Quantcast

Latest Clostridium Stories

35136_web
2011-08-22 20:02:26

Novel approach may offer treatment for other bacterial diseases Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years. In the U.S., several million...

2011-08-16 14:45:22

A team of researchers at the Department of Energy's BioEnergy Science Center (BESC) have pinpointed the exact, single gene that controls ethanol production capacity in a microorganism. This discovery could be the missing link in developing biomass crops that produce higher concentrations of ethanol at lower costs. "The Department of Energy relies on the scientific discoveries of its labs and research centers to improve the production of clean energy sources," said Energy Secretary Steven Chu....

2011-06-27 07:00:00

MARLBOROUGH, Mass., June 27, 2011 /PRNewswire/ -- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest-cost production of cellulosic ethanol, and the University of Massachusetts Amherst, today announced two significant intellectual property (IP) advances that extend the patent estate for their unique ethanol-producing microorganism, Clostridium phytofermentans, also known as the Q Microbe®. The United States...

2011-06-16 14:56:00

VOORHEES, N.J., June 16, 2011 /PRNewswire/ -- Hypervirulent strains and increased frequency of Clostridium difficile infection (CDI) have resulted in more severe disease and increased costs to the healthcare system in recent years. Fortunately, innovative therapies for the treatment of CDI are emerging. In order to improve patient outcomes, healthcare professionals must be aware of special considerations for at-risk populations, as well as the changing epidemiology, emerging novel...

2011-06-08 12:30:00

FRANKFURT, Germany, June 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that new data on Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada. The studies found that repeated injections of XEOMIN were safe and effective in the treatment of blepharospasm and...

2011-05-27 14:55:00

SILVER SPRING, Md., May 27, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Clostridium difficile (C. difficile) is a bacterium that can cause diarrhea and lead to colitis, other serious intestinal conditions, and death in severe cases. C. difficile bacteria are found in the stool of an...

2011-05-20 06:00:00

MALVERN, Pa., May 20, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company received a $7.5 million regulatory milestone from Pfizer, Inc. (Pfizer) following the first sale of XIAPEX® in Germany, a major EU market. XIAPEX is now available for sale in the United Kingdom, Germany, Denmark, Sweden, Finland, Norway and Austria. XIAPEX is a new non-surgical treatment option for Dupuytren's...

2011-05-19 08:57:00

EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI. The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days...

2011-05-12 17:26:00

BUFFALO, N.Y., May 12, 2011 /PRNewswire-USNewswire/ -- The warmer the summer, the more dead birds and fish you can expect to see along the shores of Lake Erie, according to a recent study led by Alicia Perez-Fuentetaja, research scientist of the Great Lakes Center at Buffalo State College and associate professor of biology. The study appears online in the Journal of Great Lakes Research. (Photo: http://photos.prnewswire.com/prnh/20110512/DC01391) The deaths result from outbreaks of type...


Latest Clostridium Reference Libraries

0_d6572564d3305dc462f4641398789e11
2011-04-15 13:32:47

Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...

More Articles (1 articles) »
Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related